Request Trial
anitavarma
Anita Varma and Chuck Larsen, White & Case
6 December 2017Pharma

LSPN Europe 2017: PTAB facing criticism over political independence

A lawyer speaking at the Life Sciences Patent Network (LSPN) Europe conference has said the US Patent Trial and Appeal Board (PTAB) has come under fire for not being politically independent.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Pharma
Influential Women in IP 2026: Who made the list?
7 July 2026   Leading women from the pharmaceutical and biotechnology sectors are among the more than 100 professionals recognised in a newly released Influential Women in IP 2026 list, which celebrates leadership, expertise and innovation.
Pharma
What’s at stake in Australia’s biggest pharma patent appeal in years?
1 July 2026   Otsuka v Sun Pharma could redefine which pharmaceutical patents qualify for patent term extensions, with major implications for innovator companies, generic manufacturers and the future of market exclusivity in the country.
Pharma
US life sciences damages averaged $33.5m between 2019-2025
18 June 2026   Despite a slowdown in US patent litigation, life sciences remains one of the most active sectors—but companies are using a wider than ever IP toolkit, says a new study.


Editor's picks

What’s at stake in Australia’s biggest pharma patent appeal in years?
Pharma
What’s at stake in Australia’s biggest pharma patent appeal in years?
1 July 2026

Editor's picks

Pharma
What’s at stake in Australia’s biggest pharma patent appeal in years?
1 July 2026
Biotech
Novartis and Eli Lilly sign separate $1.9bn novel drug deals
25 June 2026
Biotech
Insilico lands potential $2.5bn AI biotech partnership
22 June 2026
Pharma
US life sciences damages averaged $33.5m between 2019-2025
18 June 2026
Americas
Hikma v Amarin: Six takeaways from the pivotal ruling
9 June 2026
Americas
Takeda to appeal $885m jury verdict over ‘pay-for-delay’ scheme
19 May 2026

More features

Exelixis opens two-front patent dispute over Cabometyx copies
UPC upholds injunction in Invisalign maker’s software dispute with rival
BioNTech and Pfizer secure big European win over mRNA patent
Pillsbury nabs ‘veteran’ IP litigator and trial lawyer from Goodwin
Influential Women in IP 2026: Who made the list?
WilmerHale trade secrets expert moves to new firm
UPC revives patent, but timing sinks Guardant’s appeal
China’s medtech shake-up forces rethink on pricing, IP and innovation